Covid-19: Solution Group to supply CanSino vaccine in Malaysia

FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS

KUALA LUMPUR (Bernama): Solution Group Bhd’s (SGB) wholly-owned subsidiary, Solution Biologics Sdn Bhd (SolBio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine for use against Covid-19.

In a statement, the group said the finished product agreement allows SolBio to purchase and CanSino to supply the finish product vaccine for emergency use in Malaysia.